NCT/Study#
NCT05910801 /
ACCRU-LY-2101
Tafasitamab, Lenalidomide and Venetoclax Combination Therapy for Relapsed or Refractory Mantle Cell Lymphoma (V-MIND): A Phase II Study with Safety Lead-in
DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
